Holen Sie sich die Stockscreener-App
0.2653
0.26%
0.0013
Schlusskurs vom Vortag:
$0.2666
Offen:
$0.284
24-Stunden-Volumen:
402.53K
Relative Volume:
0.25
Marktkapitalisierung:
$62.81M
Einnahmen:
$175.04M
Nettoeinkommen (Verlust:
$-44.52M
KGV:
-1.4739
EPS:
-0.18
Netto-Cashflow:
$-56.05M
1W Leistung:
+12.22%
1M Leistung:
+6.92%
6M Leistung:
-63.76%
1J Leistung:
-74.78%
1-Tages-Spanne:
$0.2608
$0.284
1-Wochen-Bereich:
$0.2394
$0.2977
52-Wochen-Spanne:
$0.1951
$1.48
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Firmenname
Adaptimmune Therapeutics Plc Adr
Sektor
Branche
Telefon
44 1235 430000
Adresse
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Vergleichen Sie ADAP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.2662 | 62.81M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.50 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.54 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
612.00 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.17 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
246.26 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-09 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-05-28 | Eingeleitet | Barclays | Underweight |
| 2020-04-22 | Eingeleitet | Mizuho | Neutral |
| 2019-08-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-05-31 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-30 | Fortgesetzt | Citigroup | Buy |
| 2019-05-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | Eingeleitet | Wells Fargo | Market Perform |
| 2016-10-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | Eingeleitet | Raymond James | Outperform |
| 2016-02-25 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | BofA/Merrill | Neutral |
| 2015-06-01 | Eingeleitet | Guggenheim | Buy |
| 2015-06-01 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile
Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex
Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India
Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa
Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com
Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com
Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639 - Investing.com
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Finanzdaten der Adaptimmune Therapeutics Plc Adr-Aktie (ADAP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adaptimmune Therapeutics Plc Adr-Aktie (ADAP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lunger John | Chief Patient Supply Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Bertrand William C JR | Chief Operating Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '25 |
Sale |
0.58 |
30,601 |
17,773 |
44,327 |
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):